Companies › Karyopharm Therapeutics
2 active drug programs in 103 registered trials: 58 Phase 2, 32 Phase 1, 11 Phase 3, 2 Phase 4; Hematology, Oncology, Genitourinary, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Selinexor (KPT-330) Exportin-1 inhibitor | XPO1 | Phase 3 | Endometrial Cancer; Myelofibrosis; Diffuse Large B-cell Lymphoma; Relapsed/Refractory Diffuse Large B-cell Lymphoma … | Dec 2026 |
| Bortezomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Multiple Myeloma, Refractory; Hematological Neoplasms; Newly Diagnosed; Multiple Myeloma … | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT00492050 | Bortezomib | Phase 2 | Waldenstrom's Macroglobulinemia | Oncology | Feb 2021 |
| NCT06853080 | Bortezomib | Phase 2 | Atypical Teratoid/Rhabdoid Tumors (AT/RTs) | Oncology | Dec 2023 |
| NCT05597345 | Selinexor (KPT-330) | Phase 2 | Smoldering Multiple Myeloma | Oncology | Oct 2024 |
| NCT03589222 | Selinexor (KPT-330) | Phase 2 | Refractory Multiple Myeloma | Oncology | Aug 2026 |
| NCT03589222 | Bortezomib | Phase 2 | Refractory Multiple Myeloma | Oncology | Aug 2026 |
| NCT04562870 | Selinexor (KPT-330) | Phase 2 | Myelofibrosis | Oncology | Sep 2026 |
| NCT04925193 | Selinexor (KPT-330) | Phase 2 | Multiple Myeloma in Relapse | Oncology | Nov 2026 |
| NCT06559553 | Selinexor (KPT-330) | Phase 1 | NKTCL | Oncology | Dec 2026 |
| NCT05979363 | Bortezomib | Phase 2 | Plasma Cell Leukemia | Oncology | Dec 2026 |
| NCT02227251 | Selinexor (KPT-330) | Phase 2 | Diffuse Large B-cell Lymphoma | Oncology | Dec 2026 |
| NCT04442022 | Selinexor (KPT-330) | Phase 2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Oncology | Dec 2026 |
| NCT02091245 | Selinexor (KPT-330) | Phase 1 | Relapsed Acute Lymphoblastic Leukemia (ALL) | Oncology | Dec 2026 |
| NCT01208662 | Bortezomib | Phase 3 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT06029998 | Bortezomib | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Dec 2026 |
| NCT06342466 | Bortezomib | Phase 2 | Systemic Amyloidosis | Metabolic and endocrine | Dec 2026 |
| NCT00378105 | Bortezomib | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT03643549 | Bortezomib | Phase 1 | Glioblastoma | Oncology | Dec 2026 |
| NCT05833893 | Selinexor (KPT-330) | Phase 2 | nk/T-cell Lymphoma | Oncology | Dec 2026 |
| NCT06822972 | Selinexor (KPT-330) | Phase 2 | Multiple Myeloma in Relapse | Oncology | Dec 2026 |
| NCT05698147 | Selinexor (KPT-330) | Phase 1 | Central Nervous System Lymphoma | Oncology | Dec 2026 |
| NCT03844360 | Bortezomib | Phase 4 | Hematological Neoplasms | Oncology | Dec 2026 |
| NCT01863550 | Bortezomib | Phase 3 | Plasma Cell Myeloma | Oncology | Dec 2026 |
| NCT03993262 | Bortezomib | Phase 2 | Autoimmune Encephalitis | Immunology | Dec 2026 |
| NCT06418477 | Bortezomib | Phase 2 | Monoclonal Gammopathy of Renal Significance | Genitourinary | Dec 2026 |
| NCT05514990 | Bortezomib | Phase 1 | Recurrent Plasma Cell Myeloma | Oncology | Dec 2026 |
| NCT07369739 | Selinexor (KPT-330) | Phase 2 | Lymphohistiocytosis | Hematology | Jan 2027 |
| NCT04991103 | Bortezomib | Phase 2 | Multiple Myeloma | Oncology | Jan 2027 |
| NCT06517511 | Selinexor (KPT-330) | Phase 2 | Diffuse Large B Cell Lymphoma | Oncology | Jan 2027 |
| NCT05736419 | Bortezomib | Phase 2 | Sickle Cell Disease | Hematology | Feb 2027 |
| NCT03620903 | Bortezomib | Phase 2 | Waldenstrom Macroglobulinemia | Oncology | Feb 2027 |
| NCT01695941 | Bortezomib | Phase 1 | Recurrent B-Cell Non-Hodgkin Lymphoma | Oncology | Mar 2027 |
| NCT05736978 | Selinexor (KPT-330) | Phase 2 | AML | Oncology | Mar 2027 |
| NCT01861314 | Bortezomib | Phase 1 | Acute Myeloid Leukemia | Oncology | Mar 2027 |
| NCT02343042 | Selinexor (KPT-330) | Phase 1 | Multiple Myeloma | Oncology | Apr 2027 |
| NCT05870917 | Bortezomib | Phase 2 | Plasma Cell Leukemia | Oncology | Apr 2027 |
| NCT02835222 | Selinexor (KPT-330) | Phase 2 | Untreated Adult Acute Myeloid Leukemia | Oncology | Apr 2027 |
| NCT05736965 | Selinexor (KPT-330) | Phase 2 | AML, Adult | Oncology | Apr 2027 |
| NCT05333458 | Selinexor (KPT-330) | Phase 2 | Advanced Alveolar Soft Part Sarcoma | Oncology | May 2027 |
| NCT06966154 | Selinexor (KPT-330) | Phase 1 | Natural Killer/T-cell Lymphoma | Oncology | May 2027 |
| NCT00644228 | Bortezomib | Phase 3 | DS Stage I Multiple Myeloma | Oncology | Jun 2027 |
| NCT05980806 | Selinexor (KPT-330) | Phase 2 | Myelofibrosis | Hematology | Jun 2027 |
| NCT05980806 | Selinexor (KPT-330) | Phase 2 | Myelofibrosis | Hematology | Jun 2027 |
| NCT03147885 | Selinexor (KPT-330) | Phase 1 | Diffuse Large B-Cell Lymphoma | Oncology | Jun 2027 |
| NCT05432804 | Selinexor (KPT-330) | Phase 1 | Recurrent Glioblastoma, IDH-Wildtype | Oncology | Jun 2027 |
| NCT07094464 | Selinexor (KPT-330) | Phase 1 | TP53-mutated MDS and AML | Oncology | Jun 2027 |
| NCT04915248 | Bortezomib | Phase 2 | Plasmablastic Lymphoma | Oncology | Jul 2027 |
| NCT07479979 | Selinexor (KPT-330) | Phase 1 | Relapse Multiple Myeloma | Oncology | Jul 2027 |
| NCT05470491 | Bortezomib | Phase 1 | HIV | Oncology | Jul 2027 |
| NCT03136146 | Bortezomib | Phase 2 | Recurrent Acute Lymphoblastic Leukemia | Oncology | Aug 2027 |
| NCT05665140 | Bortezomib | Phase 2 | Newly Diagnosed Multiple Myeloma | Oncology | Aug 2027 |
| NCT04898894 | Selinexor (KPT-330) | Phase 1 | Acute Leukemia of Ambiguous Lineage in Relapse | Oncology | Sep 2027 |
| NCT02112916 | Bortezomib | Phase 3 | Adult T Acute Lymphoblastic Leukemia | Oncology | Sep 2027 |
| NCT06169215 | Selinexor (KPT-330) | Phase 2 | Multiple Myeloma | Oncology | Sep 2027 |
| NCT06169215 | Bortezomib | Phase 2 | Multiple Myeloma | Oncology | Sep 2027 |
| NCT05099003 | Selinexor (KPT-330) | Phase 1 | Malignant Glioma | Oncology | Sep 2027 |
| NCT03763162 | Bortezomib | Phase 2 | Recurrent Plasma Cell Myeloma | Oncology | Oct 2027 |
| NCT05035745 | Selinexor (KPT-330) | Phase 1 | Advanced Refractory Solid Tumors | Oncology | Nov 2027 |
| NCT06409702 | Bortezomib | Phase 4 | Newly Diagnosed | Oncology | Nov 2027 |
| NCT04775550 | Bortezomib | Phase 2 | High-risk Smoldering Multiple Myeloma | Oncology | Dec 2027 |
| NCT04756401 | Selinexor (KPT-330) | Phase 2 | Recurrent Plasma Cell Myeloma | Oncology | Dec 2027 |
The 60 nearest readouts of 103 trials; the rest in the app.
Cash and short-term investments of $65m on 2026-06-30; operating cash outflow about $97m a year; runway about 8 months at that burn, to Mar 2027; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Geron Aura Biosciences Disc Medicine Kind Pharmaceuticals Dogwood Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.